litlas
Log inCreate account

Eric B. Haura

Active 2000–2025

124
Papers
21,821
Citations
79
h-index
117
i10-index

Citations

Citations per year for Eric B. Haura1971: 1 citations1996: 1 citations1999: 1 citations2001: 6 citations2002: 27 citations2003: 58 citations2004: 83 citations2005: 106 citations2006: 121 citations2007: 169 citations2008: 160 citations2009: 162 citations2010: 192 citations2011: 203 citations2012: 205 citations2013: 201 citations2014: 216 citations2015: 239 citations2016: 222 citations2017: 222 citations2018: 266 citations2019: 732 citations2020: 920 citations2021: 1,001 citations2022: 793 citations2023: 648 citations2024: 916 citations2025: 473 citations2026: 17 citations1972–1995: no citations, so these years are not shown1997–1998: no citations, so these years are not shown2000: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,326 citing papers, 27.5% of this breakdownChina: 1,966 citing papers, 16.2% of this breakdownUnited Kingdom: 591 citing papers, 4.9% of this breakdownGermany: 505 citing papers, 4.2% of this breakdownItaly: 493 citing papers, 4.1% of this breakdownFrance: 401 citing papers, 3.3% of this breakdownCanada: 383 citing papers, 3.2% of this breakdownSpain: 351 citing papers, 2.9% of this breakdownJapan: 348 citing papers, 2.9% of this breakdownAustralia: 296 citing papers, 2.4% of this breakdownSouth Korea: 294 citing papers, 2.4% of this breakdownNetherlands: 250 citing papers, 2.1% of this breakdown
0%27.5%Other 23.9%

Institutions

Fields

  • Medicine52.3%
  • Biochemistry, Genetics and Molecular Biology36.5%
  • Immunology and Microbiology5.1%
  • Chemistry1.2%
  • Computer Science1%
  • Neuroscience0.8%
  • Other3.1%

Topics

  • Lung Cancer Treatments and Mutations7.1%
  • Cancer Immunotherapy and Biomarkers3.5%
  • Cytokine Signaling Pathways and Interactions3.3%
  • Cancer Genomics and Diagnostics2.7%
  • Lung Cancer Research Studies2.6%
  • Lung Cancer Diagnosis and Treatment2.1%
  • Other78.7%

Coauthors

All papers

Open in search
  1. Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial

    Authors: Ben Creelan, Chao Wang, Jamie K. Teer, Eric M. Toloza, Jiqiang Yao, Sungjune Kim, Ana Marie Landin, John E. Mullinax, James J. Saller, Andreas Saltos, David Noyes, Leighann B. Montoya, Wesley Curry, Shari Pilon‐Thomas, Alberto Chiappori, Tawee Tanvetyanon, Frederic J. Kaye, Zachary Thompson, Sean Yoder, Bin Fang, John M. Koomen, Amod A. Sarnaik, Dung‐Tsa Chen, José R. Conejo-García, Eric B. Haura, Scott Antonia - Nature Medicine 2021 cited by 421

  2. Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study

    Authors: Keunchil Park, Eric B. Haura, Natasha B. Leighl, Paul Mitchell, Catherine A. Shu, Nicolas Girard, Santiago Viteri, Ji‐Youn Han, Sang‐We Kim, Chee Khoon Lee, Joshua K. Sabari, Alexander I. Spira, Tsung‐Ying Yang, Dong‐Wan Kim, Ki Hyeong Lee, Rachel E. Sanborn, José Trigo, Kōichi Goto, Jong‐Seok Lee, James Chih‐Hsin Yang, Ramaswamy Govindan, Joshua Bauml, Pilar Garrido, Matthew Krebs, Karen L. Reckamp, John Xie, Joshua C. Curtin, Nahor Haddish‐Berhane, Amy Roshak, Dawn Millington, Patricia Lorenzini, Meena Thayu, Roland E. Knoblauch, Byoung Chul Cho - Journal of Clinical Oncology 2021 cited by 632

  3. Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes

    Authors: James McKay, Rayjean J Hung, Younghun Han, Xuchen Zong, Robert Carreras‐Torres, David C. Christiani, Neil E. Caporaso, Mattias Johansson, Xiangjun Xiao, Yafang Li, Jinyoung Byun, Alison M. Dunning, Karen A. Pooley, David C. Qian, Xuemei Ji, Geoffrey Liu, Maria Timofeeva, Stig E. Bojesen, Xifeng Wu, Loı̈c Le Marchand, Demetrius Albanes, Heike Bickeböller, Melinda C. Aldrich, William S. Bush, Adonina Tardón, Gad Rennert, M. Dawn Teare, John K. Field, Lambertus A. Kiemeney, Philip Lazarus, Aage Haugen, Stephen Lam, Matthew B. Schabath, Angeline S. Andrew, Hongbing Shen, Yun‐Chul Hong, Jian‐Min Yuan, Pier Alberto Bertazzi, Angela Cecilia Pesatori, Yuanqing Ye, Nancy Diao, Li Su, Ruyang Zhang, Yonathan Brhane, Natasha B. Leighl, Jakob Sidenius Johansen, Anders Mellemgaard, Walid Saliba, Christopher A. Haiman, Lynne R. Wilkens, Ana Fernández‐Somoano, Guillermo Fernández‐Tardón, Erik H.F.M. van der Heijden, Jin Hee Kim, Juncheng Dai, Zhibin Hu, Michael P.A. Davies, Michael W. Marcus, Hans Brunnström, Jonas Manjer, Olle Melander, David C. Muller, Kim Overvad, Antonia Trichopoulou, ­Rosario ­Tumino, Jennifer A. Doherty, Matt P Barnett, Chu Chen, Gary E. Goodman, Angela Cox, Fiona Taylor, Penella J. Woll, Irene Brüske, H‐Erich Wichmann, Judith Manz, Thomas R Muley, Angela Risch, Albert Rosenberger, Kjell Grankvist, Mikael Johansson, Frances A. Shepherd, Ming‐Sound Tsao, Susanne M. Arnold, Eric B. Haura, Ciprian Bolca, Ivana Holcátová, Vladimí­r Janout, Milica Kontić, Jolanta Lissowska, Anush Mukeria, Simona Ognjanovic, Tadeusz Orłowski, Ghislaine Scélo, Beata Świątkowska, Давид Заридзе, Per Bakke, Vidar Skaug, Shanbeh Zienolddiny, Eric J. Duell, Lesley M. Butler and 40 more - Nature Genetics 2017 cited by 794

  4. Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs

    Authors: Mark G. Kris, Bruce E. Johnson, Lynne D. Berry, David J. Kwiatkowski, A. John Iafrate, Ignacio I. Wistuba, Marileila Varella‐Garcia, Wilbur A. Franklin, Samuel L. Aronson, Pei-Fang Su, Yu Shyr, D. Ross Camidge, Lecia V. Sequist, Bonnie S. Glisson, Fadlo R. Khuri, Edward B. Garon, William Pao, Charles M. Rudin, Joan H. Schiller, Eric B. Haura, Mark A. Socinski, Keisuke Shirai, Heidi Chen, Giuseppe Giaccone, Marc Ladanyi, Kelly Kugler, John D. Minna, Paul A. Bunn - JAMA 2014 cited by 1,744

  5. The Unfolded Protein Response Mediator PERK Governs Myeloid Cell-Driven Immunosuppression in Tumors through Inhibition of STING Signaling

    Authors: Eslam Mohamed, Rosa A. Sierra, Jimena Trillo-Tinoco, Yu Cao, Patrick Innamarato, Kyle K. Payne, Álvaro de Mingo Pulido, Jay K. Mandula, Shuzhong Zhang, Paul Thevenot, Subir Biswas, Sarah K. Abdalla, Tara Lee Costich, Kay Hänggi, Carmen M. Anadon, Elsa R. Flores, Eric B. Haura, Shikhar Mehrotra, Shari Pilon‐Thomas, Brian Ruffell, David H. Munn, Juan R. Cubillos‐Ruiz, José R. Conejo-García, Paulo C. Rodrı́guez - Immunity 2020 cited by 218

  6. Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability

    Authors: Rosalie C. Sears, Faison Nuckolls, Eric B. Haura, Yoichi Taya, Katsuyuki Tamai, Joseph R. Nevins - Genes & Development 2000 cited by 1,427

  7. Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial

    Authors: Jamie E. Chaft, Filiz Öezkan, Mark G. Kris, Paul A. Bunn, Ignacio I. Wistuba, David J. Kwiatkowski, Dwight H. Owen, Yan Tang, Bruce E. Johnson, Jay M. Lee, Gerard Lozanski, Maciej Pietrzak, Michał T. Seweryn, Woo Yul Byun, Katja Schulze, Alan Nicholas, Ann Johnson, Jessica M. Grindheim, Stephanie Hilz, David S. Shames, Chris Rivard, Eric M. Toloza, Eric B. Haura, Ciaran McNamee, G. Alexander Patterson, Saiama N. Waqar, Valerie W. Rusch, David P. Carbone, LCMC study investigators, Saiama N. Waqar, Elaine Shum, Misako Nagasaka, Marianna Koczywas, Edward B. Garon, David J. Finley, David Ross Camidge, Jennifer W. Carlisle, Justin D. Blasberg - Nature Medicine 2022 cited by 237

  8. Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial

    Authors: Byoung Chul Cho, Dong‐Wan Kim, Alexander I. Spira, Jorge Gómez, Eric B. Haura, Sang‐We Kim, Rachel E. Sanborn, Eun Kyung Cho, Ki Hyeong Lee, Anna Minchom, Jong Seok Lee, Ji‐Youn Han, Misako Nagasaka, Joshua K. Sabari, Sai‐Hong Ignatius Ou, Patricia Lorenzini, Joshua Bauml, Joshua C. Curtin, Amy Roshak, Grace Gao, John Xie, Meena Thayu, Roland E. Knoblauch, Keunchil Park - Nature Medicine 2023 cited by 101

  9. HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma

    Authors: Hong Zheng, Weipeng Zhao, Cihui Yan, Crystina C. Watson, Michael T. Massengill, Mengyu Xie, Chris Massengill, David Noyes, Gary V. Martinez, Roha Afzal, Zhihua Chen, Xiubao Ren, Scott Antonia, Eric B. Haura, Brian Ruffell, Amer A. Beg - Clinical Cancer Research 2016 cited by 351

  10. Cell Type–specific Adaptive Signaling Responses to KRASG12C Inhibition

    Authors: Hitendra S. Solanki, Eric A. Welsh, Bin Fang, Victoria Izumi, Lancia Darville, Brandon Stone, Ryan Franzese, Sandip Chavan, Fumi Kinose, Denis Imbody, John M. Koomen, Uwe Rix, Eric B. Haura - Clinical Cancer Research 2021 cited by 100

  11. IGF-binding proteins secreted by cancer-associated fibroblasts induce context-dependent drug sensitization of lung cancer cells

    Authors: Lily L. Remsing Rix, Natália J. Sumi, Qianqian Hu, Bina Desai, Annamarie T. Bryant, Xueli Li, Eric A. Welsh, Bin Fang, Fumi Kinose, Brent M. Kuenzi, Y. Ann Chen, Scott Antonia, Christine M. Lovly, John M. Koomen, Eric B. Haura, Andriy Marusyk, Uwe Rix - Science Signaling 2022 cited by 72

  12. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis

    Authors: Guilian Niu, Kenneth L. Wright, Mei Huang, Lanxi Song, Eric B. Haura, James Turkson, Shumin Zhang, Tianhong Wang, Dominic Sinibaldi, Domenico Coppola, Richard Heller, Lee M. Ellis, James G. Karras, Jacqueline Bromberg, Drew M. Pardoll, Richard Jove, Hua Yu - Oncogene 2002 cited by 1,207

  13. Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma

    Authors: Matthew B. Schabath, E A Welsh, William J. Fulp, Lieping Chen, Jamie K. Teer, Zachary Thompson, Brienne E. Engel, Min Xie, Anders Berglund, Ben Creelan, S. Antonia, Jhanelle E. Gray, Steven A. Eschrich, D-T Chen, W. Douglas Cress, Eric B. Haura, Amer A. Beg - Oncogene 2015 cited by 445

  14. Resistance to targeted therapies as a multifactorial, gradual adaptation to inhibitor specific selective pressures

    Authors: Robert Vander Velde, Nara Yoon, Viktoriya Marusyk, Arda Durmaz, Andrew Dhawan, Daria Miroshnychenko, Diego Lozano‐Peral, Bina Desai, Olena V. Balynska, Jan Poleszhuk, Kenian Liu, Mingxiang Teng, Mohamed E. Abazeed, Omar Y. Mian, Aik Choon Tan, Eric B. Haura, Jacob G. Scott, Andriy Marusyk - Nature Communications 2020 cited by 143

  15. Src kinases as therapeutic targets for cancer

    Authors: Lori C. Kim, Lanxi Song, Eric B. Haura - Nature Reviews Clinical Oncology 2009 cited by 692

  16. Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non–Small Cell Lung Cancer

    Authors: Jhanelle E. Gray, Andreas Saltos, Tawee Tanvetyanon, Eric B. Haura, Ben Creelan, Scott Antonia, Michael Shafique, Hong Zheng, Wenjie Dai, James J. Saller, Zhihua Chen, Nishan Tchekmedyian, Kristen Goas, Ram Thapa, Theresa A. Boyle, Dung‐Tsa Chen, Amer A. Beg - Clinical Cancer Research 2019 cited by 140

  17. Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non–Small Cell Lung Cancer

    Authors: Alberto Chiappori, Ben Creelan, Tawee Tanvetyanon, Jhanelle E. Gray, Eric B. Haura, Ram Thapa, Margaret L. Barlow, Zhihua Chen, Dung Tsa Chen, Amer A. Beg, Theresa A. Boyle, Julio Castro, Liza Morgan, Erick J. Morris, Mehreteab Aregay, Felipe K. Hurtado, Luigi Manenti, Scott Antonia - Clinical Cancer Research 2022 cited by 69

  18. TGF-β–inducible microRNA-183 silences tumor-associated natural killer cells

    Authors: Sarah S. Donatelli, Junmin Zhou, Danielle L. Gilvary, Erika A. Eksioglu, Xianghong Chen, W. Douglas Cress, Eric B. Haura, Matthew B. Schabath, Domenico Coppola, Sheng Wei, Julie Y. Djeu - National Academy of Sciences, Proceedings of the National Academy of Sciences 2014 cited by 214

  19. Poziotinib in Treatment-Naive NSCLC Harboring HER2 Exon 20 Mutations: ZENITH20-4, A Multicenter, Multicohort, Open-Label, Phase 2 Trial (Cohort 4)

    Authors: Robin Cornelissen, Arsela Prelaj, Sophie Sun, Christina S. Baik, Mirjana Wollner, Eric B. Haura, Hirva Mamdani, Jonathan W. Riess, Federico Cappuzzo, Marina Chiara Garassino, John V. Heymach, Mark A. Socinski, Szu‐Yun Leu, Gajanan Bhat, François Lebel, Xiuning Le - Journal of Thoracic Oncology 2023 cited by 55

  20. An immunoproteomic approach to characterize the CAR interactome and signalosome

    Authors: María C. Ramello, Ismahène Benzaïd, Brent M. Kuenzi, Maritza Lienlaf-Moreno, Wendy Kandell, Daniel N. Santiago, Mibel Pabón-Saldaña, Lancia Darville, Bin Fang, Uwe Rix, Sean Yoder, Anders Berglund, John M. Koomen, Eric B. Haura, Daniel Abate‐Daga - Science Signaling 2019 cited by 155

  21. Proteogenomic landscape of squamous cell lung cancer

    Authors: Paul A. Stewart, Eric A. Welsh, Robbert J.C. Slebos, Bin Fang, Victoria Izumi, Matthew Chambers, Guolin Zhang, Ling Cen, Fredrik Pettersson, Yonghong Zhang, Zhihua Chen, Chia‐Ho Cheng, Ram Thapa, Zachary Thompson, Katherine Fellows, Jewel M. Francis, James J. Saller, Tania Mesa, Chaomei Zhang, Sean Yoder, Gina M. DeNicola, Amer A. Beg, Theresa A. Boyle, Jamie K. Teer, Y. Ann Chen, John M. Koomen, Steven A. Eschrich, Eric B. Haura - Nature Communications 2019 cited by 121

  22. CRESTONE: Initial efficacy and safety of seribantumab in solid tumors harboring NRG1 fusions.

    Authors: Daniel R. Carrizosa, Mark E. Burkard, Yasir Y. Elamin, Jayesh Desai, Shirish M. Gadgeel, Jessica Jiyeong Lin, Saiama N. Waqar, David R. Spigel, Young Kwang Chae, Parneet Cheema, Eric B. Haura, Stephen V. Liu, Danny Nguyen, Karen L. Reckamp, Frank Tsai, Valerie M. Jansen, Alexander Drilon, Sai‐Hong Ignatius Ou, D. Ross Camidge, Tejas Patil - Journal of Clinical Oncology 2022 cited by 40

  23. Phase I Study of JNJ-74699157 in Patients with Advanced Solid Tumors Harboring the KRAS G12C Mutation

    Authors: Judy Wang, Patricia Martín-Romano, Philippe A. Cassier, Melissa L. Johnson, Eric B. Haura, Laurie Lenox, Yue Guo, Nibedita Bandyopadhyay, Michael J. Russell, Elizabeth Shearin, Josh Lauring, Laëtitia Dahan - The Oncologist 2022 cited by 55

  24. Phase IB Study of Osimertinib in Combination with Navitoclax in EGFR-mutant NSCLC Following Resistance to Initial EGFR Therapy (ETCTN 9903)

    Authors: Erin M. Bertino, Ryan D. Gentzler, Sarah Clifford, Jill Kolesar, Alona Muzikansky, Eric B. Haura, Zofia Piotrowska, D. Ross Camidge, Thomas E. Stinchcombe, Christine Hann, Jyoti Malhotra, Liza C. Villaruz, Cloud P. Paweletz, Christie J. Lau, Lynette M. Sholl, Naoko Takebe, Jeffrey A. Moscow, Geoffrey I. Shapiro, Pasi A. Jänne, Geoffrey R. Oxnard - Clinical Cancer Research 2020 cited by 43